Literature DB >> 17106760

Chronic obstructive pulmonary disease severity and cardiovascular outcomes.

Suellen M Curkendall1, Stephan Lanes, Cynthia de Luise, Mary Rose Stang, Judith K Jones, Dewei She, Earl Goehring.   

Abstract

OBJECTIVE: To identify predictors of chronic obstructive pulmonary disease (COPD) severity and assess the relation between COPD severity and risk of cardiovascular outcomes. STUDY DESIGN AND
SETTING: A cohort of patients with diagnosed and treated COPD was compiled from the Saskatchewan Health longitudinal databases. We used multivariate modeling to identify predictors of hospitalization for COPD as an indicator of COPD severity, and we used the model to characterize patients according to quintiles of COPD severity. These severity levels were used as independent variables in multivariate models of cardiovascular outcomes.
RESULTS: Determinants of COPD severity included emphysema, recent nebulizer use, home oxygen services, corticosteroid use, frequent bronchodilator use, pneumonia and prior COPD exacerbation. The 20% of patients with the highest COPD severity were 1.27 (CI: 1.07-1.50) times more likely to have arrhythmia, 1.25 (CI: 1.07-1.46) times more likely to have ischemic heart disease, 1.38 (CI: 1.11-1.71) times more likely to have angina, 2.28 (CI: 1.95-2.66) times more likely to have congestive heart failure, and 1.63 (CI: 1.22-2.16) times more likely to die of cardiovascular causes than the least severe 20% of patients.
CONCLUSIONS: Patients with more severe COPD, as defined by our model, had higher cardiovascular morbidity and mortality than patients with less severe COPD.

Entities:  

Mesh:

Year:  2006        PMID: 17106760     DOI: 10.1007/s10654-006-9066-1

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  23 in total

1.  Lung function and risk of myocardial infarction and sudden cardiac death.

Authors:  G D Friedman; A L Klatsky; A B Siegelaub
Journal:  N Engl J Med       Date:  1976-05-13       Impact factor: 91.245

2.  Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins.

Authors:  G Engström; P Lind; B Hedblad; P Wollmer; L Stavenow; L Janzon; F Lindgärde
Journal:  Circulation       Date:  2002-11-12       Impact factor: 29.690

3.  Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease.

Authors:  R Antonelli Incalzi; L Fuso; M De Rosa; F Forastiere; E Rapiti; B Nardecchia; R Pistelli
Journal:  Eur Respir J       Date:  1997-12       Impact factor: 16.671

4.  Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies.

Authors:  Samy Suissa
Journal:  Am J Respir Crit Care Med       Date:  2003-03-27       Impact factor: 21.405

Review 5.  Systemic effects of chronic obstructive pulmonary disease.

Authors:  A G N Agustí; A Noguera; J Sauleda; E Sala; J Pons; X Busquets
Journal:  Eur Respir J       Date:  2003-02       Impact factor: 16.671

6.  Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study.

Authors:  D J Hole; G C Watt; G Davey-Smith; C L Hart; C R Gillis; V M Hawthorne
Journal:  BMJ       Date:  1996-09-21

7.  Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease.

Authors:  A M Schols; J Slangen; L Volovics; E F Wouters
Journal:  Am J Respir Crit Care Med       Date:  1998-06       Impact factor: 21.405

8.  Left ventricular dysfunction in deteriorating patients with chronic obstructive pulmonary disease.

Authors:  M L Render; A S Weinstein; A S Blaustein
Journal:  Chest       Date:  1995-01       Impact factor: 9.410

9.  Recent trends in the use of inhaled beta 2-adrenergic agonists and inhaled corticosteroids in Saskatchewan.

Authors:  B Habbick; M J Baker; M McNutt; D W Cockcroft
Journal:  CMAJ       Date:  1995-11-15       Impact factor: 8.262

10.  Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD.

Authors:  Karin H Groenewegen; Annemie M W J Schols; Emiel F M Wouters
Journal:  Chest       Date:  2003-08       Impact factor: 9.410

View more
  30 in total

1.  Lung function, percent emphysema, and QT duration: The Multi-Ethnic Study of Atherosclerosis (MESA) lung study.

Authors:  Hilary F Armstrong; Gina S Lovasi; Elsayed Z Soliman; Susan R Heckbert; Bruce M Psaty; John H M Austin; Jerry A Krishnan; Eric A Hoffman; Craig Johnson; Matthew J Budoff; Karol E Watson; R Graham Barr
Journal:  Respir Med       Date:  2016-12-08       Impact factor: 3.415

2.  Budesonide mitigates pathological changes in animal model Of COPD through reducing neutrophil elastase expression.

Authors:  Lihong Wang; Bin Zhang; Zhu Li; Junhong Li; Qing Liu; Wuzhuang Sun
Journal:  Int J Clin Exp Med       Date:  2015-04-15

3.  Chronic obstructive pulmonary disease and the risk of cardiovascular diseases.

Authors:  Cornelia Schneider; Ulrich Bothner; Susan S Jick; Christoph R Meier
Journal:  Eur J Epidemiol       Date:  2010-02-27       Impact factor: 8.082

4.  Sexual dysfunction in men with COPD: impact on quality of life and survival.

Authors:  Eileen G Collins; Sahar Halabi; Mathew Langston; Timothy Schnell; Martin J Tobin; Franco Laghi
Journal:  Lung       Date:  2012-07-03       Impact factor: 2.584

5.  Use of cardioselective β-blockers and overall death and cardiovascular outcomes in patients with COPD: a population-based cohort study.

Authors:  Yaa-Hui Dong; Chia-Hsuin Chang; Li-Chiu Wu; Mei-Shu Lai
Journal:  Eur J Clin Pharmacol       Date:  2016-07-22       Impact factor: 2.953

6.  Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD.

Authors:  R Graham Barr; Bartolome R Celli; David M Mannino; Thomas Petty; Stephen I Rennard; Frank C Sciurba; James K Stoller; Byron M Thomashow; Gerard M Turino
Journal:  Am J Med       Date:  2009-04       Impact factor: 4.965

7.  Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study).

Authors:  Pilar de Lucas-Ramos; Jose Luis Izquierdo-Alonso; Jose Miguel Rodriguez-Gonzalez Moro; Jesus Fernandez Frances; Paz Vaquero Lozano; Jose M Bellón-Cano
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-10-01

8.  A method to study the effect of bronchodilators on smoke retention in COPD patients: study protocol for a randomized controlled trial.

Authors:  W D van Dijk; P T J Scheepers; R Cremers; J W M Lenders; W Klerx; C van Weel; T R J Schermer; Y Heijdra
Journal:  Trials       Date:  2011-02-10       Impact factor: 2.279

9.  A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use.

Authors:  David Price; Yumi Asukai; Jaithri Ananthapavan; Bill Malcolm; Amr Radwan; Ian Keyzor
Journal:  Appl Health Econ Health Policy       Date:  2013-06       Impact factor: 2.561

10.  Comorbidity and sex-related differences in mortality in oxygen-dependent chronic obstructive pulmonary disease.

Authors:  Magnus P Ekström; Claes Jogréus; Kerstin E Ström
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.